Publications
Reese, S., Farhang, N., Poulson, R., Parkman, G., and Weiss, J. Nanoscale imaging of collagen gels with focused ion beam milling and scanning electron microscopy. Biophysical Journal. Oct 2016; 111(8): 1797- 1804.
Kircher, DA, Trombetti, KA, Silvia, MR, Parkman, GL, Fischer, GM, Angel, SN, Stehn, CM, Strain, SC, Grossman, AH, Duffy, KL, Boucher, KM, McMahon, M, Davies, MA, Mendoza, MC, VanBrocklin, MW, and Holmen, SL. AKT1-E17K activates focal adhesion kinase and promotes melanoma brain metastasis. Molecular Cancer Research. Sept 2019; 17(9): 1787-1800.
Foth M, Parkman G, Battistone B, McMahon M. RAC1 mutation is not a predictive biomarker for PI3’-kinase-β- selective pathway targeted therapy. Pigment Cell and Melanoma Research. 2020. 33(5): 719-730. PMID: 32406574.
Vaishnavi A, Scherzer M, Kinsey C, Parkman G, Truong A, Ghazi P, Schuman S, Battistone B, Garrido- Laguno I, McMahon M. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Reports. 2020. 32(5):107994. PMID: 32755586.
Parkman GL, Kircher DA, Stehn CM, McMahon M, Holmen SL. Model-dependent outcomes: Sex as a biological variable in preclinical mouse models of melanoma. Pigment Cell and Melanoma Res. 2020;00:1-4.
Burnett WJ, Burnett DM, Parkman G, Ramstead A, Contreras N, Gravley W, Holmen SL, Williams MA, VanBrocklin MW. Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy. Cancers (Basel). 2021 Sep 4;13(17):4462. doi: 10.3390/cancers13174462. PMID: 34503272; PMCID: PMC8431599.
Parkman GL, Foth M, Kircher DA, Holmen SL, McMahon M. Role of the PI3’-kinase signaling pathway in melanoma. Experimental Dermatology. 2021 Oct 30. doi: 10.1111/exd.14489. Epub ahead of print. PMID: 34717019.
Parkman GL, Turapov T, Kircher DA, Burnett WJ, Stehn CM, O'Toole K, Culver KM, Chadwick AT, Elmer RC, Flaherty R, Stanley KA, Foth M, Lum DH, Judson-Torres RL, Friend JE,
VanBrocklin MW, McMahon M, Holmen SL. Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression. Mol Cancer Ther. 2024 Mar 4;23(3):301-315. doi: 10.1158/1535- 7163.MCT-23-0474. PMID: 37931033; PMCID: PMC10932877.
Parkman GL*, Holmen SL. A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies. J Cancer Immunol (Wilmington). 2024;6(3):92-99. doi: 10.33696/cancerimmunol.6.089. PMID: 39381117; PMCID: PMC11460539.
*Corresponding author
Almazan J, Turapov T, Kircher DA, Stanley KA, Culver K, Medellin AP, Field MN, Parkman GL, Colman H, Coma S, Pachter JA, Holmen SL. Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastases. Cell Rep Med. 2025 Feb 18;6(2):101943. doi: 10.1016/j.xcrm.2025.101943. Epub 2025 Feb 7. PMID: 39922199; PMCID: PMC11866499.
Parkman GL*, Xu X*, Holmen SL*, Karreth FA*. The Roles of PTEN in Melanoma Suppression. Pigment Cell Melanoma Res. 2025 Sep;38(5):e70054. doi: 10.1111/pcmr.70054. PMID: 40976930; PMCID: PMC12451098.
*Corresponding authors